Tareq Abadl: Persistent Anti-β2GPI IgG Is Not a Coincidence – It’s Pathology
Tareq Abadl, Medical Laboratory Specialist and Director of the Blood Bank at Dr. Abdelkader Al-Mutawakkil Hospital, shared a post on LinkedIn:
“β2 Glycoprotein I Antibodies — Made Simple
Many people hear the name β2 Glycoprotein I antibodies and get confused. Let’s break it down clearly
What is β2 Glycoprotein I?
β2 Glycoprotein I (β2GPI) is a normal plasma protein that binds to phospholipids and plays a role in regulating coagulation.
What does the test measure?
It detects autoantibodies against β2GPI, which are a core laboratory criterion for diagnosing Antiphospholipid Syndrome (APS).
IgG vs IgM — What’s the difference?
β2GPI – IgM
- Often rises in early or transient immune responses
- May be associated with infections, inflammation, or immune stress
- Can be temporary and disappear on repeat testing
- Lower diagnostic weight for APS
β2GPI – IgG
- Clinically more significant
- Persistent elevation strongly supports APS diagnosis
- More clearly associated with:
- Thrombosis
- Recurrent pregnancy loss
- Placental insufficiency
Bottom line: IgG is more reliable and more dangerous than IgM in terms of complications.
Important Laboratory Points
The test must be repeated after ≥12 weeks to confirm persistence
- Never interpret it alone
- APS diagnosis requires a panel, including:
- Lupus Anticoagulant (LA)
- Anticardiolipin antibodies (aCL)
- Anti-β2 Glycoprotein I antibodies
- Medium to high titers are required — low positives may be clinically irrelevant
Advanced lab note (important):
- IgG antibodies targeting Domain I of β2GPI are the most pathogenic and most strongly linked to thrombosis
- Solid-phase assays (ELISA/CLIA) must follow international APS cut-offs, not manufacturer-only ranges
Simple analogy Anti-β2GPI antibodies are like someone sabotaging traffic control
Blood flow loses balance to congestion to clots
If IgG is present and persistent, this is not coincidence — it’s pathology.”

Find more posts featuring Tareq Abadl on Hemostasis Today.
-
Feb 2, 2026, 16:06Christian Heiss։ When Diabetes and PAD Overlap, Cardiovascular and Limb Risks Rise
-
Feb 2, 2026, 16:02Shiny K. Kajal: Platelet Transfusion Is a Therapy – Not a Reflex
-
Feb 2, 2026, 15:37Rana Saifi: An Exciting Time for the Bleeding Disorders Community
-
Feb 2, 2026, 13:08Hammam Alminshawi: Time is Brain – Optimizing MRI for Acute Ischemic Stroke
-
Feb 2, 2026, 12:53Lucie Gelon: Proud to Share My 1st Achievements in The Scientific and Platelet World
-
Feb 2, 2026, 12:32Matthew Flick on SARS-CoV-2 Spike Protein and Coagulation Biology
-
Feb 2, 2026, 11:24Shivanand Kumatagi Delivers an Interactive Session on ISBT128 Standard
-
Feb 2, 2026, 11:03Meghan Delaney Congratulates Ruchika Goel for The Recent Paper on Pediatric Transfusion
-
Feb 2, 2026, 10:31Fayad Al-Haimus: Is Giving TXA Within “3 Hours” Really Enough?